Medical AI

A Swedish pharma company's trial is progressing faster than expected, but the real story is the potential paradigm shift for millions suffering from a neglected disease.

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

Skin Analytics' DERM Zero is the first AI to get Class III certification for autonomous skin cancer checks on a smartphone, promising to transform access.

A new study validates iMDx's precision diagnostic tech, setting the stage for a strategic assault on the centralized lab model for organ rejection monitoring.

Verastem Oncology's new drug enters a pivotal trial for pancreatic cancer, targeting a notorious mutation with a novel dual-action mechanism.

A $1.2M seed round for orthopaedic AI firm Maia isn't just startup news. It signals a systemic shift from generalist AI to specialized digital engines.

A new Illinois wellness center combines FDA-cleared depression therapy with cosmetic treatments, raising critical questions about the future of healthcare delivery.

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

A strategic alliance between Behavioral Health Insights and HealthVerity promises to bridge the data divide in mental health, revolutionizing research and care.

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

With the acquisition of an FDA-cleared app, UpRight Science is turning smartphones into medical devices to predict and prevent falls in older adults.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

A small med-tech firm is betting its future on fingerprint sweat. Can its novel drug test pass the FDA's rigorous trials and disrupt a billion-dollar market?

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Arima Genomics' award-winning Aventa test is revolutionizing lymphoma diagnostics by seeing cancer in 3D, moving beyond 2D methods to find what others miss.

As the home healthcare market booms, BrightStar Care's top franchise ranking reveals a powerful model blending clinical rigor with a scalable franchise system.

A biotech firm's non-hallucinogenic drug just passed a key safety test. Could this novel approach finally disrupt the challenging world of alcohol use disorder?

Apollo Athenaa's new handbook addresses caregiver burnout, offering a vital resource to the unsung heroes of India's growing cancer crisis.